In conclusion, we found that the KF4 anti-CELA1 antibody and purified human AAT were similarly effective at preventing emphysema in a mouse model of AAT-deficient emphysema but that there was no benefit to combined therapy. Here, CELA1 is linked to pulmonary emphysema.